NCT00138567已完成3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 530
- 试验地点
- 3
- 主要终点
- Safety during 104 weeks of treatment
研究概览
简要总结
This is a 52-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to metformin in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 78 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only patients successfully completing study CLAF237A2309 are eligible
- •Written informed consent
- •Ability to comply with all study requirements
排除标准
- •Premature discontinuation from CLAF237A2309
- •Other protocol-defined exclusion criteria may apply
结局指标
主要结局
Safety during 104 weeks of treatment
Change from baseline in HbA1c at 104 weeks
次要结局
- Change in fasting plasma glucose between 52 weeks and 104 weeks
- Change from baseline in fasting plasma glucose at 104 weeks
- Change from baseline in HOMA B at 104 weeks
- Change in HOMA B between 52 weeks and 104 weeks
- Change in HbA1c between 52 weeks and 104 weeks
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138619Novartis478
已完成
3 期
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138541Novartis440
已完成
4 期
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsType 2 Diabetes Mellitus (T2DM)NCT02002221Novartis Pharmaceuticals156
已完成
3 期
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01582230Novartis Pharmaceuticals293
已完成
3 期
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01497522Novartis Pharmaceuticals183